[go: up one dir, main page]

WO2006031715A2 - Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique - Google Patents

Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique Download PDF

Info

Publication number
WO2006031715A2
WO2006031715A2 PCT/US2005/032381 US2005032381W WO2006031715A2 WO 2006031715 A2 WO2006031715 A2 WO 2006031715A2 US 2005032381 W US2005032381 W US 2005032381W WO 2006031715 A2 WO2006031715 A2 WO 2006031715A2
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
phenyl
compound
methyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/032381
Other languages
English (en)
Other versions
WO2006031715A3 (fr
Inventor
James C. Lanter
Zhihua Sui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN2005800381110A priority Critical patent/CN101056862B/zh
Priority to JP2007531421A priority patent/JP5031568B2/ja
Priority to AU2005285035A priority patent/AU2005285035B2/en
Priority to ES05800947T priority patent/ES2422204T3/es
Priority to EP05800947.3A priority patent/EP1791821B1/fr
Priority to CA002579514A priority patent/CA2579514A1/fr
Publication of WO2006031715A2 publication Critical patent/WO2006031715A2/fr
Publication of WO2006031715A3 publication Critical patent/WO2006031715A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention is directed to novel imidazolidin-2-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. More particularly, the compounds of the present invention are useful in the treatment of prostate carcinoma, benign prostatic hyperplasia (BPH), hirsitutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and / or as a male performance enhancer.
  • BPH benign prostatic hyperplasia
  • hirsitutism hirsitutism
  • alopecia anorexia nervosa
  • breast cancer acne
  • AIDS cachexia
  • cachexia cachexia
  • Androgens are the anabolic steroid hormones of animals, controlling muscle and skeletal mass, the maturation of the reproductive system, the development of secondary sexual characteristics and the maintenance of fertility in the male.
  • testosterone is converted to estrogen in most target tissues, but androgens themselves may play a role in normal female physiology, for example, in the brain.
  • the chief androgen found in serum is testosterone, and this is the effective compound in tissues such as the testes and pituitary.
  • testosterone is converted to dihydrotestosterone (DHT) by the action of 5 ⁇ -reductase.
  • DHT dihydrotestosterone
  • androgens Like all steroid hormones, androgens bind to a specific receptor inside the cells of target tissues, in this case the androgen receptor. This is a member of the nuclear receptor transcription factor family. Binding of androgen to the receptor activates it and causes it to bind to DNA binding sites adjacent to target genes. From there it interacts with coactivator proteins and basic transcription factors to regulate the expression of the gene. Thus, via its receptor, androgens cause changes in gene expression in cells. These changes ultimately have consequences on the metabolic output, differentiation or proliferation of the celll that are visible in the physiology of the target tissue.
  • Non-steroidal agonists and antagonists of the androgen receptor are useful in the treatment of a variety of disorders and diseases. More particularly, agonists of the androgen receptor could be employed in the treatment of prostate cancer, benign prostatic hyperplasia, hirsutism in women, alopecia, anorexia nervosa, breast cancer and acne. Antagonists of the androgen receptor could be employed in male contraception, male performance enhancement, as well as in the treatment of cancer, AIDS, cachexia, and other disorders.
  • the present invention is directed to a compound of formula (I)
  • R 1 is selected from the group consisting of hydrogen and lower alkyl
  • R 2 and R 3 are independently selected from the group consisting of lower alkyl, halogen substituted lower alkyl, -CH(OH)-(lower alkyl), -C(O)- (lower alkyl), -C(O)-(lower alkoxy), -C(O)-N(R A ) 2 , -C(O)-N(R B ) 2 provided that one of R 2 or R 3 is either lower alkyl or halogen substituted lower alkyl; wherein each R A is independently selected from hydrogen or lower alkyl; wherein each R B is independently selected from hydrogen, lower alkyl and aryl provided that if present, only one R B is aryl; wherein the aryl is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, lower alkyl, halogen substituted lower alkyl, lower alkoxy, halogen substituted lower alkoxy, cyano, nitro, amino, lower alkylamino or
  • R 4 is selected from the group consisting halogen, hydroxy, carboxy, lower alkyl, halogen substituted lower alkyl, lower alkoxy, halogen substituted lower alkoxy, cyano, nitro, amino, lower alkylamino, di(lower alkyl)amino, -C(O)-(lower alkyl), -C(O)-(lower alkoxy), -C(O)-N(R A ) 2) -S(O) 0 - 2 -(lower alkyl), -SO 2 -N(R A ) 2 , -N(R A )-C(O)-(lower alkyl), -N(R A )-C(O)- (halogen substituted lower alkyl) and aryl; wherein each R A is independently selected from hydrogen or lower alkyl; wherein the aryl is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, lower alky
  • the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described herein.
  • the invention relates to a pharmaceutical composition made by mixing any of the compounds described herein and a pharmaceutically acceptable carrier.
  • the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described herein and a pharmaceutically acceptable carrier.
  • the invention also provides methods of treating disorders and conditions modulated by the androgen receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of any of the compounds or pharmaceutical compositions described herein.
  • invention provides a method for treating an androgen receptor modulated disorder selected from the group consisting of prostate carcinoma, benign prostatic hyperplasia, hirsutism, or for male contraception, in a subject in need thereof comprising administering to the subject an effective amount of any of the compounds or pharmaceutical compositions described herein.
  • Another example of the invention is the use of any of the compounds described herein in the preparation of a medicament for treating: (a) prostate carcinoma, (b) benign prostatic hyperplasia, (c) hirsutism, (d) alopecia, (e) anorexia nervosa, (f) breast cancer, (g) acne, (h) AIDS, (i) cachexia, for (j) male contraception, or for (k) male performance enhancement, in a subject in need thereof.
  • DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to compounds of formula (I),
  • the compounds of the present invention are modulators of the androgen receptor and are useful for the treatment of prostate carcinoma, benign prostatic hyperplasia (BPH), hirsitutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and / or as a male performance enhancer.
  • BPH benign prostatic hyperplasia
  • hirsitutism hirsitutism
  • alopecia anorexia nervosa
  • breast cancer acne
  • AIDS cachexia
  • cachexia cachexia
  • halogen shall mean chlorine, bromine, fluorine and iodine.
  • alkyl includes straight and branched chains.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like.
  • lower when used with alkyl means a carbon chain composition of 1-4 carbon atoms.
  • halogen substituted lower alkyl shall mean a lower alkyl group as defined above wherein one or more of the hydrogen atoms is replaced with a halogen atom. Suitable examples include, but are not limited to, trifluoromethyl, 2,2,2-trifluoro-eth-1- yl, chloromethyl, fluoromethyl and the like.
  • fluorinated lower alkyl shall mean a lower alkyl group as defined above wherein one or more of the hydrogen atoms is replaced with a fluorine atom. Suitable examples include, but are not limited to, fluoromethyl, fluoroethyl, trifluoromethyl, 2,2,2-trifluoro-eth-i -yl, and the like.
  • alkoxy shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.
  • cycloalkyl shall mean any stable four to eight membered monocyclic, saturated ring system, for example cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • aryl shall refer to unsubstituted carbocylic aromatic groups such as phenyl, naphthyl, and the like.
  • heteroaryl shall denote any five or six membered, monocyclic aromatic ring structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to three additional heteroatoms independently selected from the group consisting of O, N and S; or a nine or ten membered, bicyclic aromatic ring structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to four additional heteroatoms independently selected from the group consisting of O, N and S.
  • the heteroaryl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
  • heteroaryl groups include, but are not limited to, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, purazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furazanyl, indolizinyl, indolyl, isoindolinyl, indazolyl, benzofuryl, benzothienyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, isothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, and the like.
  • substituents e.g., cycloalkyl, aryl, heteroaryl, etc
  • that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of substituents.
  • a "phenyl- (CrC 6 alkyl)-aminocarbonyl-(Ci-C 6 alkyl)" substituent refers to a group of the formula
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes, but is not limited to, alleviation of the symptoms of the disease or disorder being treated.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • compounds according to this invention may accordingly exist as enantiomers.
  • compounds possess two or more chiral centers they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
  • the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers
  • these isomers may be separated by conventional techniques such as preparative chromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoyl-L-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound.
  • the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
  • the salts of the compounds of this invention refer to "pharmaceutically acceptable salts.”
  • Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • alkali metal salts e.g., sodium or potassium salts
  • alkaline earth metal salts e.g., calcium or magnesium salts
  • suitable organic ligands e.g., quaternary ammonium salts.
  • Representative pharmaceutically acceptable salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pa
  • acids and bases which may be used in the preparation of pharmaceutically acceptable salts include the following: acids including acetic acid, 2,2-dichloroactic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1 S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, 2- hydrocy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid,
  • a catalyst such as toluene sulfonic acid, benzene sulfonic acid, sulfuric acid and the like
  • the compound of formula (III) is reacted with a reducing agent such as hydrogen gas (in the presence of a palladium catalyst), sodium borohydrde, sodium cyanoborohydride and the like in an organic solvent such as methanol, ethanol, THF and the like, to yield the corresponding compound of formula (IV).
  • a reducing agent such as hydrogen gas (in the presence of a palladium catalyst), sodium borohydrde, sodium cyanoborohydride and the like in an organic solvent such as methanol, ethanol, THF and the like, to yield the corresponding compound of formula (IV).
  • the compound of formula (IV) is de-protected according to known methods, for example, by reacting with an acid such as trifluoromethanesulfonic acid, HCI, trifluoroacetic acid, and the like, in an organic solvent or mixture thereof such as methanol/water, ethanol/water, THF, and the like, to yield the corresponding compound of formula (V).
  • an acid such as trifluoromethanesulfonic acid, HCI, trifluoroacetic acid, and the like
  • organic solvent or mixture thereof such as methanol/water, ethanol/water, THF, and the like
  • the compound of formula (V) is reacted with a reagent such as carbonyl diimidazole, p-nitrophenylchloroformate, triphosgene, phosgene and the like in the presence of a base such as triethylamine, pyridine, and the like, in an organic solvent such as THF, dichloromethane and the like, to yield the corresponding compound of formula Ia.
  • a base such as sodium hydroxide, potassium hydroxide and the like, in an organic solvent or mixture thereof such as methanol/water, ethanol/water, THF, and the like, to yield the corresponding compound of formula (Ib).
  • the compound of formula (Ib) is reacted with oxalyl chloride in a solvent such as dichloromethane, dichloroethane and the like, optionally in the presence of a catalytic amount of DMF, to form the intermediate acid chloride which is reacted with an appropriately substituted primary amine to afford the corresponding compound of formula (Ic).
  • a solvent such as dichloromethane, dichloroethane and the like, optionally in the presence of a catalytic amount of DMF
  • EXAMPLE 6 1 -(4-Fluoro-phenyl)-4-methyl-2-oxo-imidazolidine-4-carboxylic acid (4- cyano-3-trifluoromethyl-phenyl)-amide (6a).
  • mice Male Sprague Dawley or Wistar rats (Charles River, 200-30Og) were used for each preparation. The day before preparing the cytosol, the rats were castrated using standard surgical procedures.
  • the rats were euthanized by carbon dioxide asphyxiation.
  • the rat prostates were quickly removed and placed on ice in pre-chilled, pre-weighed 50 ml_ plastic tubes. No more than five prostates were placed into one tube. The tubes were then weighed and the prostate tissue wet weights calculated.
  • To the chilled prostate tissue was then added 1 mL/mg tissue of chilled homogenization buffer.
  • the homogenization buffer was freshly prepared by mixing 10 mM Tris.HCI, pH 7.4, 1 mM sodium molybdate, 1.5 mM EDTA, 1 mM dithiothreitol, 10% (v/v) glycerol and 1% protease inhibitor cocktail (Sigma P 8340).
  • the prostate tissue was homogenized in a cold room using a pre-chilled Polytron PT3000 homogenizer (Brinkmann). Homogenization was performed at a speed setting of 20, three times for 10 sec bursts. The tubes containing the prostate tissue was kept on ice while homogenizing. The homogenate was allowed to rest on ice for 20 sec between bursts. The homogenate was then placed into pre-chilled 3 ml_ polycarbonate ultracentrifuge tubes and centrifuged in the TLA-100 rotor of a TL-100 ultracentrifuge for 12 min at 100,000 rpm at 4 0 C. The resulting supernatant was stored in 1 mL aliquots at -80°C until needed.
  • Binding to the androgen receptor was determined according to the protocol described in Example 86 using the above prepared rat cytosol. % Inhibition was determined by testing dilutions of the test compound (usually duplicates of 10 ⁇ M) in the binding assay. Counts per well were measured and percents of inhibition determined. Androgen receptor binding IC 50 S were determined by testing serial dilutions of the test compound (usually duplicate ten half-log dilutions starting at 10 ⁇ M) in the binding assay. Counts per well were measured and IC 5 oS determined by linear regression.
  • COS-7 cells were plated in 96-well plates at 20,000 cells per well, in a solution of DMEM/F12 (GJBCO) containing 10% (v/v) charcoal-treated fetal bovine serum (Hyclone) and lacking phenol red. The cells were then incubated overnight at 37 0 C in 5% (v/v) humidified CO 2 .
  • GJBCO DMEM/F12
  • Hyclone charcoal-treated fetal bovine serum
  • Test compound solutions were prepared by diluting the test compound in 100% (v/v) DMSO, if necessary. Each dilution yielded a solution which was 625X the final desired test concentration.
  • a 2.5 nM dilution of tritiated methyl-trienolone in DMEM/F12 lacking phenol red ([ 3 H]RI 881 ; Perkin- Elmer) was prepared.
  • a 15 ml_ or 50 mL sterile centrifuge tube a dilution in DMEM/F12 of the adenovirus AdEasy+rAR at a moi of 1 :50 per well was prepared.
  • the medium was removed from the 96-well plates by inversion and the plates dried very briefly, inverted, on a sterile towel. As soon as possible after medium removal, 40 ⁇ l_ of the diluted test compound was added to each well, in duplicate. To each well was then added 40 ⁇ L of the 2.5 nM [ 3 H]RI 881 and 20 ⁇ L of the diluted adenovirus. The plates were then incubated for 48 hours at 37°C in 5% (v/v) humidified CO 2 .
  • Percent inhibition was determined by testing dilutions of the test compound (usually duplicates of 10 ⁇ M) in the binding assay. Counts per well were measured and percents of inhibition determined. Androgen receptor binding IC 5 oS were determined by testing serial dilutions of the test compound (usually duplicate ten half-log dilutions starting at 10 ⁇ M) in the binding assay. Counts per well were measured and IC 50 S determined by linear regression.
  • L929 cells were plated in 96-well plates at 20,000 cells per well, in DMEM/F12 (GIBCO) containing 10% (v/v) charcoal-treated fetal bovine serum (Hyclone) and lacking phenol red. The plates were then incubated overnight at 37 ° C in 5% (v/v) humidified CO 2 .
  • Test compound dilutions were prepared in 100% (v/v) DMSO, if necessary.
  • Each dilution was made to 1250X the final desired assay concentration.
  • 2 mL of DMEM/F12 lacking phenol red was pipetted into the wells of a 2-mL 96-well assay block.
  • 4 ⁇ l_ of the 1250X test compound dilutions were pipetted into each well of the assay block. The mixtures within the well were then carefully mixed by pipette.
  • a 2.5 nM (2.5X) dilution of R1881 (methyl-trienolone) in DMEM/F12 lacking phenol red was prepared.
  • a solution containing an equal volume of DMEM to the first and an equal volume of 100% (v/v) DMSO to the volume of R1881 used in the first tube was prepared.
  • a 15 mL or 50 mL sterile centrifuge tube a dilution in DMEM/F12 of the adenovirus AdEasy+rAR at an moi of 1 :500 per well was prepared. The medium was removed from the 96-well plates by inversion and dried, inverted, very briefly. As soon as possible after medium removal, 40 ⁇ L of the diluted unlabeled test compound was added to each well, in duplicate.
  • L929 AR percent activity was determined by testing dilutions of the test compound using a concentration of 3000 nM unless otherwise noted. L929 percent inhibition was determined by testing dilutions of the test compound using a concentration of 3000 nM.
  • EC 50 S and IC 50 S were determined by testing serial dilutions of the test compound (usually duplicate ten half-log dilutions starting at 10 ⁇ M). Luciferase activity per well were measured and EC 50 S and IC 50 S determined by linear regression.
  • Immature approximately 50 g castrated male Sprague Dawley rats (Charles River) were treated once daily for five days with test compound (usually given orally at 40 mg/kg in a volume of 0.3 ml_, in 30% cyclodextrin or 0.5% methylcellulose vehicle) and with testosterone propionate (given subcutaneously by injection at the nape of the neck at 2 mg/kg, in a volume of 0.1 ml_ in sesame oil). On the sixth day, the rats were euthanized by asphyxiation in carbon dioxide. Ventral prosatates and seminal vesicles were removed and their wet weights determined.
  • Test compound activity was determined as the percent inhibition of testosterone-enhanced tissue weights, with a vehicle-treated control group set to zero percent and a testosterone alone-treated control group set to 100%. A test compound was said to be "active" if the non weight adjusted prostate weight was ⁇ 60 mg or ⁇ 84 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés d'imidazolidine-2-one de structure conforme à la formule I : a, b, R1, R2, R3, et R4 sont tels que définis dans la description. L'invention concerne aussi des compositions pharmaceutiques contenant ces dérivés et leur utilisation pour le traitement de troubles et d'affections modulés par le récepteur androgénique.
PCT/US2005/032381 2004-09-10 2005-09-09 Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique Ceased WO2006031715A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2005800381110A CN101056862B (zh) 2004-09-10 2005-09-09 作为选择性雄激素受体调节剂（sarms）的咪唑烷-2-酮衍生物
JP2007531421A JP5031568B2 (ja) 2004-09-10 2005-09-09 選択的アンドロゲン受容体モジュレーター（ｓａｒｍｓ）としての新規なイミダゾリジン−２−オン誘導体
AU2005285035A AU2005285035B2 (en) 2004-09-10 2005-09-09 Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS)
ES05800947T ES2422204T3 (es) 2004-09-10 2005-09-09 Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
EP05800947.3A EP1791821B1 (fr) 2004-09-10 2005-09-09 Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique
CA002579514A CA2579514A1 (fr) 2004-09-10 2005-09-09 Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60915704P 2004-09-10 2004-09-10
US60/609,157 2004-09-10

Publications (2)

Publication Number Publication Date
WO2006031715A2 true WO2006031715A2 (fr) 2006-03-23
WO2006031715A3 WO2006031715A3 (fr) 2006-07-20

Family

ID=36060597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032381 Ceased WO2006031715A2 (fr) 2004-09-10 2005-09-09 Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique

Country Status (8)

Country Link
US (2) US7531565B2 (fr)
EP (1) EP1791821B1 (fr)
JP (1) JP5031568B2 (fr)
CN (1) CN101056862B (fr)
AU (1) AU2005285035B2 (fr)
CA (1) CA2579514A1 (fr)
ES (1) ES2422204T3 (fr)
WO (1) WO2006031715A2 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055184A3 (fr) * 2004-11-16 2007-04-05 Janssen Pharmaceutica Nv Nouveaux derives heterocycliques utiles en tant que modulateurs selectifs des recepteurs des androgenes (sarms)
WO2009117109A1 (fr) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase de type 1
WO2011028112A1 (fr) * 2009-09-02 2011-03-10 Valletta Health B.V. Acide imidazole-4-carboxylique utilisé pour traiter une maladie associée à des espèces réactives d'oxygène extracellulaires
WO2012047617A1 (fr) * 2010-09-28 2012-04-12 Radius Health, Inc. Modulateurs sélectifs du récepteur des androgènes
WO2013084138A1 (fr) * 2011-12-05 2013-06-13 Novartis Ag Dérivés d'urée cyclique comme antagonistes des récepteurs des androgènes
US8487094B2 (en) 2008-07-25 2013-07-16 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8648192B2 (en) 2010-05-26 2014-02-11 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
US8673899B2 (en) 2008-05-01 2014-03-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8748444B2 (en) 2007-12-11 2014-06-10 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8754076B2 (en) 2008-07-25 2014-06-17 Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8765744B2 (en) 2010-06-25 2014-07-01 Boehringer Ingelheim International Gmbh Azaspirohexanones
US8846613B2 (en) 2010-11-02 2014-09-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
US11771682B2 (en) 2016-06-22 2023-10-03 Ellipses Pharma Ltd. AR+ breast cancer treatment methods

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
CL2008002199A1 (es) * 2007-07-26 2009-10-23 Vitae Pharmaceuticals Inc Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
US8592409B2 (en) * 2008-01-24 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2252598A2 (fr) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. Inhibiteurs 1,3-oxazepan-2-one et 1,3-diazepan-2-one de la 11 -hydroxystéroïde déshydrogénase (type1)
CA2715290A1 (fr) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibiteurs de la 11 beta-hydroxysteroide dehydrogenase 1
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2291371B1 (fr) 2008-05-01 2015-06-10 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déhydrogénase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
WO2010127237A2 (fr) * 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
GB2463514C (en) * 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
CA2799183A1 (fr) 2010-05-12 2011-11-17 Radius Health, Inc. Schemas therapeutiques
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US20190375732A1 (en) 2018-05-14 2019-12-12 David Hung Anti-cancer nuclear hormone receptor-targeting compounds
JP2022532342A (ja) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
WO2021097046A1 (fr) 2019-11-13 2021-05-20 Nuvation Bio Inc. Composés ciblant des récepteurs hormonaux nucléaires anticancéreux
CA3214408A1 (fr) 2021-03-23 2022-09-29 Nuvation Bio Inc. Composes ciblant des recepteurs hormonaux nucleaires anticancereux
WO2022235585A1 (fr) 2021-05-03 2022-11-10 Nuvation Bio Inc. Composés ciblant des récepteurs hormonaux nucléaires anticancéreux

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE102004009835A1 (de) * 2004-02-28 2005-09-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US7371743B2 (en) * 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088811B2 (en) 2004-11-16 2012-01-03 Janssen Pharmaceutica N.V. Heterocycle derivatives useful as selective androgen receptor modulators (SARMs)
US7781473B2 (en) 2004-11-16 2010-08-24 J & J Pharmaceutical Research & Development, LLC. Heterocycle derivatives useful as selective androgen receptor modulators (SARMS)
WO2006055184A3 (fr) * 2004-11-16 2007-04-05 Janssen Pharmaceutica Nv Nouveaux derives heterocycliques utiles en tant que modulateurs selectifs des recepteurs des androgenes (sarms)
US7465809B2 (en) 2004-11-16 2008-12-16 Janssen Pharmaceutica N.V. Heterocycle derivatives useful as selective androgen receptor modulators (SARMs)
US8748444B2 (en) 2007-12-11 2014-06-10 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2009117109A1 (fr) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase de type 1
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
US8673899B2 (en) 2008-05-01 2014-03-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8487094B2 (en) 2008-07-25 2013-07-16 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
US8754076B2 (en) 2008-07-25 2014-06-17 Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2011028112A1 (fr) * 2009-09-02 2011-03-10 Valletta Health B.V. Acide imidazole-4-carboxylique utilisé pour traiter une maladie associée à des espèces réactives d'oxygène extracellulaires
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
US8648192B2 (en) 2010-05-26 2014-02-11 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
US9090605B2 (en) 2010-06-16 2015-07-28 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US8765744B2 (en) 2010-06-25 2014-07-01 Boehringer Ingelheim International Gmbh Azaspirohexanones
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012047617A1 (fr) * 2010-09-28 2012-04-12 Radius Health, Inc. Modulateurs sélectifs du récepteur des androgènes
AU2011312490B2 (en) * 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
JP2013537919A (ja) * 2010-09-28 2013-10-07 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
US9920044B2 (en) 2010-09-28 2018-03-20 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US8846613B2 (en) 2010-11-02 2014-09-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2013084138A1 (fr) * 2011-12-05 2013-06-13 Novartis Ag Dérivés d'urée cyclique comme antagonistes des récepteurs des androgènes
US11771682B2 (en) 2016-06-22 2023-10-03 Ellipses Pharma Ltd. AR+ breast cancer treatment methods
US12329746B2 (en) 2016-06-22 2025-06-17 Ellipses Pharma Ltd AR+breast cancer treatment methods

Also Published As

Publication number Publication date
JP2008512492A (ja) 2008-04-24
AU2005285035B2 (en) 2012-03-22
US7531565B2 (en) 2009-05-12
US20060063819A1 (en) 2006-03-23
EP1791821A2 (fr) 2007-06-06
WO2006031715A3 (fr) 2006-07-20
US7968580B2 (en) 2011-06-28
CA2579514A1 (fr) 2006-03-23
JP5031568B2 (ja) 2012-09-19
AU2005285035A1 (en) 2006-03-23
EP1791821B1 (fr) 2013-06-05
ES2422204T3 (es) 2013-09-09
CN101056862B (zh) 2013-03-13
CN101056862A (zh) 2007-10-17
US20090215848A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
EP1791821B1 (fr) Derives d'imidazolidine-2-one en tant que modulateurs selectifs du recepteur androgenique
US6790848B2 (en) 4-piperazinylindole derivatives with 5-HT6 receptor affinity
EP1753749B1 (fr) Nouveaux derives d'indole utilises en tant que modulateurs selectifs des recepteurs androgeniques (sarms)
US7678926B2 (en) Indole derivatives as selective androgen receptor modulators (SARMS)
US9434688B2 (en) Indole derivatives as selective androgen receptor modulators (SARMS)
ZA200309258B (en) 4-Piperazinylindole derivatives with 5-HT6 receptor affinity.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005285035

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2579514

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007531421

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005285035

Country of ref document: AU

Date of ref document: 20050909

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005285035

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005800947

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580038111.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005800947

Country of ref document: EP